CN105434695A - A kind of compound Zhixuening dispersible tablet and preparation method thereof - Google Patents
A kind of compound Zhixuening dispersible tablet and preparation method thereof Download PDFInfo
- Publication number
- CN105434695A CN105434695A CN201510881588.0A CN201510881588A CN105434695A CN 105434695 A CN105434695 A CN 105434695A CN 201510881588 A CN201510881588 A CN 201510881588A CN 105434695 A CN105434695 A CN 105434695A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine extract
- disintegrating agent
- dispersible tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000000080 wetting agent Substances 0.000 claims abstract description 10
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- 229940056582 human hair preparation Drugs 0.000 claims abstract 6
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 16
- 241000180649 Panax notoginseng Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 230000002439 hemostatic effect Effects 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- -1 correctives Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 1
- 239000007968 orange flavor Substances 0.000 claims 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract description 12
- 244000046101 Sophora japonica Species 0.000 abstract description 12
- 235000010586 Sophora japonica Nutrition 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 241000922974 Callicarpa bodinieri Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 241000219304 Portulacaceae Species 0.000 description 11
- 239000003610 charcoal Substances 0.000 description 11
- 208000034507 Haematemesis Diseases 0.000 description 7
- 206010027514 Metrorrhagia Diseases 0.000 description 7
- 208000000616 Hemoptysis Diseases 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 206010046788 Uterine haemorrhage Diseases 0.000 description 5
- 208000001780 epistaxis Diseases 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域 technical field
本发明涉及制药技术领域,特别是涉及一种复方止血宁分散片及其制备方法。The invention relates to the technical field of pharmacy, in particular to a compound Zhixuening dispersible tablet and a preparation method thereof.
背景技术 Background technique
功能性子宫出血,简称功血,是一种常见的妇科疾病,是指异常的子宫出血,经诊查后未发现有全身及生殖器官器质性病变,而是由于神经内分泌系统功能失调所致。表现为月经周期不规律、经量过多、经期延长或不规则出血。崩中下血指妇女不在行经期,阴道大量出血,或持续下血淋漓不断,又称“崩中漏下”。Functional uterine bleeding, referred to as dysfunctional uterine bleeding, is a common gynecological disease. It refers to abnormal uterine bleeding. After examination, no organic diseases of the whole body and reproductive organs were found, but it was caused by dysfunction of the neuroendocrine system. . Manifested as irregular menstrual cycle, heavy menstrual flow, prolonged menstruation or irregular bleeding. Metrorrhagia refers to a woman who is not menstruating and has a large amount of vaginal bleeding, or continuous bleeding, which is also called "metrorrhagia".
发明内容 Contents of the invention
本发明的目的是提供一种复方止血宁分散片及其制备方法,具有止血、消肿、化瘀之功效。用于功能性子宫出血,崩中下血,衄血,咳血,吐血等出血症。The object of the present invention is to provide a compound Zhixuening dispersible tablet and a preparation method thereof, which have the effects of hemostasis, detumescence and blood stasis removal. For functional uterine bleeding, metrorrhagia, epistaxis, hemoptysis, hematemesis and other hemorrhagic diseases.
本发明的目的通过以下技术方案来实现:The purpose of the present invention is achieved through the following technical solutions:
一种复方止血宁分散片,由原料按以下重量百分比制备而成,中药提取物10-50%、填充剂10-80%、内加崩解剂5-50%、外加崩解剂5-15%、矫味剂0.1-10%、润湿剂0.1-20%、润滑剂0.05-20%;所述的中药提取物中,原料按重量份数,三七100-200份、紫珠草200-400份、马齿苋200-400份、炒槐花100-200份、血余炭10-50份、花蕊石50-100份。A compound Zhixuening dispersible tablet, which is prepared from raw materials according to the following weight percentages: 10-50% of traditional Chinese medicine extract, 10-80% of filler, 5-50% of internally added disintegrating agent, and 5-15% of externally added disintegrating agent %, flavoring agent 0.1-10%, wetting agent 0.1-20%, lubricant 0.05-20%; in the Chinese medicine extract, the raw materials are 100-200 parts by weight of Panax notoginseng, 200 parts of Zizhucao -400 parts, 200-400 parts of purslane, 100-200 parts of fried Sophora japonica, 10-50 parts of blood charcoal, 50-100 parts of stamen.
所述的中药提取物中,原料按优选重量份数,三七100-120份、紫珠草350-400份、马齿苋350-400份、炒槐花100-150份、血余炭30-50份、花蕊石50-80份。In the traditional Chinese medicine extract, the raw materials are in preferred parts by weight, 100-120 parts of Panax notoginseng, 350-400 parts of Zizhucao, 350-400 parts of purslane, 100-150 parts of fried Sophora japonica, 30 parts of Xue Yu charcoal -50 parts, stamens 50-80 parts.
所述的中药提取物中,原料按最佳重量份数,三七111份、紫珠草370份、马齿苋370份、炒槐花148份、血余炭37份、花蕊石74份。In the Chinese medicine extract, the raw materials are 111 parts by weight of Panax notoginseng, 370 parts of Zizhucao, 370 parts of purslane, 148 parts of fried Sophora japonica, 37 parts of blood charcoal, and 74 parts of stamen.
所述的填充剂为预胶化淀粉、甘露醇、微晶纤维素、蔗糖、乳糖、氯化钠、硫酸钙中的一种或几种的混合;所述内加崩解剂或外加崩解剂为低取代羟丙纤维素、羧甲淀粉钠、交联羧甲基纤维素钠、交联聚维酮中的一种或几种的混合;所述矫味剂为阿司帕坦、甜菊素、枸橼酸、甜橙香精中的一种或几种的混合;所述的润湿剂为水、乙醇溶液中的一种或两种的混合;所述润滑剂为硬脂酸镁、十二烷基硫酸钠、二氧化硅、滑石粉其中的一种或几种的混合。The filler is a mixture of one or more of pregelatinized starch, mannitol, microcrystalline cellulose, sucrose, lactose, sodium chloride, and calcium sulfate; The agent is a mixture of one or more of low-substituted hydroxypropyl cellulose, sodium starch glycolate, croscarmellose sodium, and crospovidone; the flavoring agent is aspartame, stevia One or more of citric acid, sweet orange essence; the wetting agent is water, ethanol solution or a mixture of two; the lubricant is magnesium stearate, One or more of sodium lauryl sulfate, silicon dioxide, and talcum powder.
所述的一种复方止血宁分散片,其制备方法的具体步骤为:Described a kind of compound Zhixuening dispersible tablet, the concrete steps of its preparation method are:
步骤1、原料预处理:按重量份数,选取优质的三七、紫珠草、马齿苋、炒槐花、血余炭、花蕊石,洗净并除杂,备用;Step 1, raw material pretreatment: select high-quality Panax notoginseng, Zizhucao, purslane, fried Sophora japonica, blood residue charcoal, stamens, wash and remove impurities, and set aside;
步骤2、提取:取以上六味中药,将三七、血余炭粉碎成细粉,花蕊石粉碎,混合后先加水煎煮2小时,再加入紫珠草、马齿苋、炒槐花,加水煎煮二次,每次2小时,合并煎液,滤过,滤液减压浓缩至70℃时,相对密度为1.24~1.28的清膏,最后在80℃减压干燥,得中药提取物;Step 2. Extraction: Take the above six traditional Chinese medicines, grind Panax notoginseng and Xueyu charcoal into fine powder, and crush stamens. After mixing, add water and boil for 2 hours, then add Zizhucao, purslane, fried Sophora japonica, add water Decoct twice, each time for 2 hours, combine the decoction, filter, and when the filtrate is concentrated under reduced pressure to 70°C, the relative density is 1.24-1.28, and finally dried under reduced pressure at 80°C to obtain the Chinese medicine extract;
步骤3、制剂:将中药提取物粉碎成细粉,过80目筛,然后加入填充剂、内加崩解剂混合均匀,加入润湿剂,采用流化床制粒技术制粒,制得整粒后,加入外加崩解剂、矫味剂、润滑剂混合均匀,用压片机压片,制成片剂;Step 3, preparation: crush the Chinese medicine extract into fine powder, pass through an 80-mesh sieve, then add a filler and an internal disintegrant to mix evenly, add a wetting agent, and granulate by fluidized bed granulation technology to obtain the whole After granulation, add additional disintegrating agent, corrective agent, lubricant and mix evenly, and compress into tablets with a tablet machine to make tablets;
步骤4、包装:按照片剂规格,分类包装,制成成品。Step 4. Packaging: According to the specifications of the photo agent, it is sorted and packaged to make a finished product.
在上述药物中:三七,散瘀止血,消肿定痛,用于咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹刺痛,跌扑肿痛,紫珠草,散瘀止血,消肿止痛,用于吐血,咯血,衄血,便血,外用治疗外伤出血,马齿苋,有清热利湿、解毒消肿、消炎、止渴、利尿作用,治热痢脓血,热淋,血淋,带下,痈肿恶疮,丹毒,痕疬,便血,子宫出血,有止血作用,槐花(炒),具有清热、凉血、止血、降压的功效,对吐血、尿血、痔疮出血、风热目赤、高血压病、高脂血症、颈淋巴结核、血管硬化、大便带血、糖尿病、视网膜炎、银屑病等有显著疗效,血余炭,收敛止血,化瘀,利尿,用于吐血,咯血,衄血,血淋,尿血,便血,崩漏,外伤出血,小便不利,花蕊石,化瘀止血,用于咯血,吐血,外伤出血,跌扑伤痛。In the above-mentioned medicines: Panax notoginseng, dissipating blood stasis to stop bleeding, reducing swelling and relieving pain, used for hemoptysis, vomiting blood, epistaxis, hematochezia, metrorrhagia, traumatic bleeding, tingling pain in chest and abdomen, tumbling and swelling pain, Zizhucao, dispelling blood stasis Hemostasis, swelling and pain relief, for vomiting blood, hemoptysis, epistaxis, blood in the stool, external treatment of traumatic bleeding, purslane, has the effects of clearing away heat and dampness, detoxifying and reducing swelling, reducing inflammation, quenching thirst, diuresis, and treating dysentery with febrile pus and blood, fever Drenching, bloody stranguria, leukorrhagia, carbuncle, swollen sores, erysipelas, scars, blood in the stool, uterine bleeding, has a hemostatic effect, Sophora japonica (stir-fried), has the effects of clearing away heat, cooling blood, hemostasis, and lowering blood pressure, and is effective for vomiting blood and hematuria , hemorrhoids bleeding, wind-heat red eyes, hypertension, hyperlipidemia, cervical lymphatic tuberculosis, hardening of the arteries, blood in the stool, diabetes, retinitis, psoriasis, etc. have significant curative effect, blood remaining charcoal, astringent and hemostasis, chemical Blood stasis, diuresis, used for vomiting blood, hemoptysis, epistaxis, stranguria, hematuria, hematochezia, metrorrhagia, traumatic bleeding, difficulty urinating, stamen stone, removing blood stasis and hemostasis, used for hemoptysis, hematemesis, traumatic bleeding, tumbling pain.
本发明的有益效果:本发明的一种复方止血宁分散片及其制备方法,具有止血、消肿、化瘀的功效,用于功能性子宫出血,崩中下血,衄血,咳血,吐血等出血症;其溶解性、分散性良好,溶出度高,生物利用度好,体内分布迅速,质量稳定,口感好,服用方便,可吞服,咀嚼,含吮或用水分散后服用,更适合老年人或小儿的患者,具有药物稳定性好,包装,运输,贮藏方便等优点,其制备方法简单易行,适用于工业生产。Beneficial effects of the present invention: a compound Zhixuening dispersible tablet of the present invention and its preparation method have the effects of hemostasis, swelling, and blood stasis, and are used for functional uterine bleeding, metrorrhagia, epistaxis, and hemoptysis. Hematemesis and other hemorrhagic diseases; it has good solubility and dispersibility, high dissolution rate, good bioavailability, rapid distribution in the body, stable quality, good taste, easy to take, can be swallowed, chewed, sucked or taken after dispersing with water, more It is suitable for elderly patients or children, and has the advantages of good drug stability, convenient packaging, transportation and storage, and the preparation method is simple and feasible, and is suitable for industrial production.
本发明的工艺特点:1、选择原料科学,生产工艺先进,其产品方便存放和使用;2、产品中药物成分易被人体吸收;3、原料来源广泛,加工艺线路短,产品易加工制造。The process characteristics of the present invention: 1. Scientific selection of raw materials, advanced production technology, and convenient storage and use of the product; 2. The medicinal ingredients in the product are easily absorbed by the human body; 3. Wide source of raw materials, short processing line, and easy processing and manufacturing of the product.
具体实施方式 detailed description
实施例1Example 1
一种复方止血宁分散片,由原料按以下重量百分比制备而成,中药提取物10-50%、填充剂10-80%、内加崩解剂5-50%、外加崩解剂5-15%、矫味剂0.1-10%、润湿剂0.1-20%、润滑剂0.05-20%;所述的中药提取物中,原料按重量份数,三七100-200份、紫珠草200-400份、马齿苋200-400份、炒槐花100-200份、血余炭10-50份、花蕊石50-100份。A compound Zhixuening dispersible tablet, which is prepared from raw materials according to the following weight percentages: 10-50% of traditional Chinese medicine extract, 10-80% of filler, 5-50% of internally added disintegrating agent, and 5-15% of externally added disintegrating agent %, flavoring agent 0.1-10%, wetting agent 0.1-20%, lubricant 0.05-20%; in the Chinese medicine extract, the raw materials are 100-200 parts by weight of Panax notoginseng, 200 parts of Zizhucao -400 parts, 200-400 parts of purslane, 100-200 parts of fried Sophora japonica, 10-50 parts of blood charcoal, 50-100 parts of stamen.
实施例2Example 2
所述的中药提取物中,原料按优选重量份数,三七100-120份、紫珠草350-400份、马齿苋350-400份、炒槐花100-150份、血余炭30-50份、花蕊石50-80份。In the traditional Chinese medicine extract, the raw materials are in preferred parts by weight, 100-120 parts of Panax notoginseng, 350-400 parts of Zizhucao, 350-400 parts of purslane, 100-150 parts of fried Sophora japonica, 30 parts of Xue Yu charcoal -50 parts, stamens 50-80 parts.
实施例3Example 3
所述的中药提取物中,原料按最佳重量份数,三七111份、紫珠草370份、马齿苋370份、炒槐花148份、血余炭37份、花蕊石74份。In the Chinese medicine extract, the raw materials are 111 parts by weight of Panax notoginseng, 370 parts of Zizhucao, 370 parts of purslane, 148 parts of fried Sophora japonica, 37 parts of blood charcoal, and 74 parts of stamen.
实施例4Example 4
所述的填充剂为预胶化淀粉、甘露醇、微晶纤维素、蔗糖、乳糖、氯化钠、硫酸钙中的一种或几种的混合;所述内加崩解剂或外加崩解剂为低取代羟丙纤维素、羧甲淀粉钠、交联羧甲基纤维素钠、交联聚维酮中的一种或几种的混合;所述矫味剂为阿司帕坦、甜菊素、枸橼酸、甜橙香精中的一种或几种的混合;所述的润湿剂为水、乙醇溶液中的一种或两种的混合;所述润滑剂为硬脂酸镁、十二烷基硫酸钠、二氧化硅、滑石粉其中的一种或几种的混合。The filler is a mixture of one or more of pregelatinized starch, mannitol, microcrystalline cellulose, sucrose, lactose, sodium chloride, and calcium sulfate; The agent is a mixture of one or more of low-substituted hydroxypropyl cellulose, sodium starch glycolate, croscarmellose sodium, and crospovidone; the flavoring agent is aspartame, stevia One or more of citric acid, sweet orange essence; the wetting agent is water, ethanol solution or a mixture of two; the lubricant is magnesium stearate, One or more of sodium lauryl sulfate, silicon dioxide, and talcum powder.
实施例5Example 5
所述的一种复方止血宁分散片,其制备方法的具体步骤为:Described a kind of compound Zhixuening dispersible tablet, the concrete steps of its preparation method are:
步骤1、原料预处理:按重量份数,选取优质的三七、紫珠草、马齿苋、炒槐花、血余炭、花蕊石,洗净并除杂,备用;Step 1, raw material pretreatment: select high-quality Panax notoginseng, Zizhucao, purslane, fried Sophora japonica, blood residue charcoal, stamens, wash and remove impurities, and set aside;
步骤2、提取:取以上六味中药,将三七、血余炭粉碎成细粉,花蕊石粉碎,混合后先加水煎煮2小时,再加入紫珠草、马齿苋、炒槐花,加水煎煮二次,每次2小时,合并煎液,滤过,滤液减压浓缩至70℃时,相对密度为1.24~1.28的清膏,最后在80℃减压干燥,得中药提取物;Step 2. Extraction: Take the above six traditional Chinese medicines, grind Panax notoginseng and Xueyu charcoal into fine powder, and crush stamens. After mixing, add water and boil for 2 hours, then add Zizhucao, purslane, fried Sophora japonica, add water Decoct twice, each time for 2 hours, combine the decoction, filter, and when the filtrate is concentrated under reduced pressure to 70°C, the relative density is 1.24-1.28, and finally dried under reduced pressure at 80°C to obtain the Chinese medicine extract;
步骤3、制剂:将中药提取物粉碎成细粉,过80目筛,然后加入填充剂、内加崩解剂混合均匀,加入润湿剂,采用流化床制粒技术制粒,制得整粒后,加入外加崩解剂、矫味剂、润滑剂混合均匀,用压片机压片,制成片剂;Step 3, preparation: crush the Chinese medicine extract into fine powder, pass through an 80-mesh sieve, then add a filler and an internal disintegrant to mix evenly, add a wetting agent, and granulate by fluidized bed granulation technology to obtain the whole After granulation, add additional disintegrating agent, corrective agent, lubricant and mix evenly, and compress into tablets with a tablet machine to make tablets;
步骤4、包装:按照片剂规格,分类包装,制成成品。Step 4. Packaging: According to the specifications of the photo agent, it is sorted and packaged to make a finished product.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510881588.0A CN105434695A (en) | 2015-12-07 | 2015-12-07 | A kind of compound Zhixuening dispersible tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510881588.0A CN105434695A (en) | 2015-12-07 | 2015-12-07 | A kind of compound Zhixuening dispersible tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434695A true CN105434695A (en) | 2016-03-30 |
Family
ID=55545626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510881588.0A Withdrawn CN105434695A (en) | 2015-12-07 | 2015-12-07 | A kind of compound Zhixuening dispersible tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434695A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103860692A (en) * | 2014-02-26 | 2014-06-18 | 江西祥润科技有限公司 | Rapid hemostatic medicament for skin wound |
| CN104352757A (en) * | 2014-11-26 | 2015-02-18 | 黑龙江省智诚医药科技有限公司 | A kind of dispersible tablet of traditional Chinese medicine for invigorating the kidney and invigorating the spleen and its preparation method |
-
2015
- 2015-12-07 CN CN201510881588.0A patent/CN105434695A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103860692A (en) * | 2014-02-26 | 2014-06-18 | 江西祥润科技有限公司 | Rapid hemostatic medicament for skin wound |
| CN104352757A (en) * | 2014-11-26 | 2015-02-18 | 黑龙江省智诚医药科技有限公司 | A kind of dispersible tablet of traditional Chinese medicine for invigorating the kidney and invigorating the spleen and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药典委员会编: "《中华人民共和国卫生部 药品标准 中药成方制剂 第二十册》", 31 December 1998 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352757A (en) | A kind of dispersible tablet of traditional Chinese medicine for invigorating the kidney and invigorating the spleen and its preparation method | |
| CN104383250A (en) | A kind of Huajuhong cough dispersible tablet and preparation method thereof | |
| CN104887952B (en) | A composition with the effect of nourishing yin and moistening the lung and its preparation method and application | |
| CN104435216A (en) | A kind of Maxing cough-relieving traditional Chinese medicine dispersible tablet and preparation method thereof | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN107890528A (en) | A kind of Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN105380993A (en) | Yindanxintai dispersible tablet and preparation method thereof | |
| CN105434695A (en) | A kind of compound Zhixuening dispersible tablet and preparation method thereof | |
| CN104436044A (en) | A kind of traditional Chinese medicine dispersible tablet for treating coronary heart disease and preparation method thereof | |
| CN106420970A (en) | Pharmaceutical composition for curing premature ovarian failure | |
| CN104435138A (en) | Paishi traditional Chinese medicine dispersible tablet and preparation method thereof | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN105106356B (en) | A kind of preparation method of Zhijiangning tablet | |
| CN104984097A (en) | A kind of traditional Chinese medicine preparation for treating essential hypertension and its application | |
| CN104435710A (en) | A traditional Chinese medicine dispersible tablet for soothing the liver and invigorating the spleen and its preparation method | |
| CN104740233B (en) | A kind of Chinese medicine composition and preparation method thereof | |
| CN105343209A (en) | Herba siegesbeckiae rheumatism dispersible tablet and preparation method thereof | |
| CN107715062A (en) | One kind is used to treat cardiovascular artery sclerosis Chinese medicine | |
| CN105381040A (en) | A kind of Hegan Lidan dispersible tablet and preparation method thereof | |
| CN102018787B (en) | Blood pressure lowering capsules and preparation process thereof | |
| CN105287931A (en) | A kind of compound Yinhua Kanggan dispersible tablet and preparation method thereof | |
| CN107441313B (en) | Traditional Chinese medicine composition, medicine and preparation method for treating decreased ovarian reserve | |
| CN118320030A (en) | Compound preparation for treating children dyspepsia and adult stomach diseases and preparation method thereof | |
| CN100384447C (en) | Medicament for treating gynecological diseases and preparation method thereof | |
| CN105535658A (en) | Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160330 |
|
| WW01 | Invention patent application withdrawn after publication |